BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

600 related articles for article (PubMed ID: 29266437)

  • 1. Genomic classifications of renal cell carcinoma: a critical step towards the future application of personalized kidney cancer care with pan-omics precision.
    Hsieh JJ; Le V; Cao D; Cheng EH; Creighton CJ
    J Pathol; 2018 Apr; 244(5):525-537. PubMed ID: 29266437
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Omics sciences and precision medicine in kidney cancer.
    Dhuli K; Micheletti C; Medori MC; Maltese PE; Tanzi B; Tezzele S; Mareso C; Generali D; Donofrio CA; Cominetti M; Fioravanti A; Riccio L; Beccari T; Ceccarini MR; Stuppia L; Gatta V; Cristoni S; Cecchin S; Marceddu G; Bertelli M
    Clin Ter; 2023; 174(Suppl 2(6)):46-54. PubMed ID: 37994748
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
    Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
    BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hereditary Renal Cell Carcinoma Syndromes: Clinical, Pathologic, and Genetic Features.
    Adeniran AJ; Shuch B; Humphrey PA
    Am J Surg Pathol; 2015 Dec; 39(12):e1-e18. PubMed ID: 26559379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Renal Cell Tumors: Understanding Their Molecular Pathological Epidemiology and the 2016 WHO Classification.
    Inamura K
    Int J Mol Sci; 2017 Oct; 18(10):. PubMed ID: 29053609
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Precision medicine from the renal cancer genome.
    Riazalhosseini Y; Lathrop M
    Nat Rev Nephrol; 2016 Nov; 12(11):655-666. PubMed ID: 27694978
    [TBL] [Abstract][Full Text] [Related]  

  • 7. What can molecular pathology contribute to the management of renal cell carcinoma?
    Stewart GD; O'Mahony FC; Powles T; Riddick AC; Harrison DJ; Faratian D
    Nat Rev Urol; 2011 May; 8(5):255-65. PubMed ID: 21487387
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumour and patient factors in renal cell carcinoma-towards personalized therapy.
    Haddad AQ; Margulis V
    Nat Rev Urol; 2015 May; 12(5):253-62. PubMed ID: 25868564
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Understanding pathologic variants of renal cell carcinoma: distilling therapeutic opportunities from biologic complexity.
    Shuch B; Amin A; Armstrong AJ; Eble JN; Ficarra V; Lopez-Beltran A; Martignoni G; Rini BI; Kutikov A
    Eur Urol; 2015 Jan; 67(1):85-97. PubMed ID: 24857407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Vancouver classification of renal tumors: Recommendations of the 2012 consensus conference of the International Society of Urological Pathology (ISUP)].
    Kristiansen G; Delahunt B; Srigley JR; Lüders C; Lunkenheimer JM; Gevensleben H; Thiesler T; Montironi R; Egevad L
    Pathologe; 2015 May; 36(3):310-6. PubMed ID: 25398389
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Possibilities of molecular diagnosis of renal cell carcinoma].
    Junker K
    Aktuelle Urol; 2014 Sep; 45(5):370-3. PubMed ID: 25230022
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Novel biomarkers in renal cell carcinoma. Identification and functional characterization].
    Macher-Göppinger S
    Pathologe; 2015 Nov; 36 Suppl 2():201-4. PubMed ID: 26362327
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictive molecular biomarkers to guide clinical decision making in kidney cancer: current progress and future challenges.
    Chan JY; Choudhury Y; Tan MH
    Expert Rev Mol Diagn; 2015 May; 15(5):631-46. PubMed ID: 25837857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Third-Line Treatment Options for Kidney Cancer.
    Posadas EM; Limvorasak S; Figlin RA
    Oncology (Williston Park); 2016 Sep; 30(9):813-5. PubMed ID: 27633411
    [No Abstract]   [Full Text] [Related]  

  • 15. Type 1 and 2 papillary renal cancers are genetically distinct.
    Balakrishnan VS
    Lancet Oncol; 2015 Dec; 16(16):e594. PubMed ID: 26596671
    [No Abstract]   [Full Text] [Related]  

  • 16. The evolving classification of renal cell neoplasia.
    Delahunt B; Srigley JR
    Semin Diagn Pathol; 2015 Mar; 32(2):90-102. PubMed ID: 25753529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy.
    Lam JS; Shvarts O; Leppert JT; Figlin RA; Belldegrun AS
    J Urol; 2005 Jun; 173(6):1853-62. PubMed ID: 15879764
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of gene expression analysis of renal cell carcinoma.
    Leppert JT; Pantuck AJ
    Expert Rev Anticancer Ther; 2006 Feb; 6(2):293-9. PubMed ID: 16445381
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High-throughput «Omics» technologies: New tools for the study of triple-negative breast cancer.
    Judes G; Rifaï K; Daures M; Dubois L; Bignon YJ; Penault-Llorca F; Bernard-Gallon D
    Cancer Lett; 2016 Nov; 382(1):77-85. PubMed ID: 26965997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comprehensive molecular tumor profiling in radiation oncology: How it could be used for precision medicine.
    Eke I; Makinde AY; Aryankalayil MJ; Ahmed MM; Coleman CN
    Cancer Lett; 2016 Nov; 382(1):118-126. PubMed ID: 26828133
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.